In conclusion, we report here three individuals with MFS and compound heterozygous mutations in FBN1, all of whom had severe aneurysmic disease, suggesting a gene dose effect of FBN1 mutations may contribute to a more severe phenotype. This evidence concerns the gene FBN1 and Marfan syndrome.